Guangdong Taienkang Pharmaceutical Co., Ltd. (301263.SZ) Latest Company News

Oct 26, 2026, 11:17 UTC
Taienkang reported third-quarter 2026 revenue of 212 million yuan, up 18.83% year over year, and net profit attributable to shareholders of 27.7637 million yuan, compared with a loss of 5.6796 million yuan a year earlier.
Source:
- finance.sina.cn
Oct 16, 2026, 08:04 UTC
China's National Medical Products Administration issued a drug registration certificate for polidocanol injection to Taienkang's wholly owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd.
Source:
- finance.sina.cn
- finance.sina.cn
Oct 15, 2026, 08:34 UTC
Taienkang controlling shareholder Zheng Hanjie completed the release of pledges on 5.67 million shares, equal to 5.35% of his holdings and 1.11% of the company’s total shares.
Source:
- finance.sina.cn
Oct 9, 2026, 07:51 UTC
China's National Medical Products Administration approved dicquafosol sodium eye drops developed by Taienkang's wholly owned subsidiary Shandong Huabo Kaisheng Biotechnology, issuing a drug registration certificate.
Source:
- finance.sina.cn
Sep 23, 2026, 08:08 UTC
Taienkang announced that its subsidiary Jiangsu Bochuangyuan Biopharmaceutical's Class 1 innovative drug CKBA cream completed Phase IIa clinical trial data for rosacea, with a 100.00% effective response rate.
Source:
- finance.sina.cn
Sep 7, 2026, 12:13 UTC
Taienkang's controlled subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. completed enrollment of the first subject in the Phase IIb clinical trial of CKBA cream for the treatment of rosacea.
Source:
- finance.sina.cn
Aug 20, 2026, 10:51 UTC
Taienkang's wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for cisplatin polymer micelles for injection.
Source:
- finance.sina.cn
Aug 7, 2026, 09:38 UTC
Tai Enkang's wholly-owned subsidiary Huabo Kaisheng won the bid for baricitinib tablets (2mg*28 tablets/box) in the 12th national centralized drug procurement.
Source:
- finance.sina.cn

301263.SZ

Taienkang reported third-quarter 2026 revenue of 212 million yuan, up 18.83% year over year, and net profit attributable to shareholders of 27.7637 million yuan, compared with a loss of 5.6796 million yuan a year earlier.

China's National Medical Products Administration issued a drug registration certificate for polidocanol injection to Taienkang's wholly owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd.

Taienkang controlling shareholder Zheng Hanjie completed the release of pledges on 5.67 million shares, equal to 5.35% of his holdings and 1.11% of the company’s total shares.

China's National Medical Products Administration approved dicquafosol sodium eye drops developed by Taienkang's wholly owned subsidiary Shandong Huabo Kaisheng Biotechnology, issuing a drug registration certificate.

Taienkang announced that its subsidiary Jiangsu Bochuangyuan Biopharmaceutical's Class 1 innovative drug CKBA cream completed Phase IIa clinical trial data for rosacea, with a 100.00% effective response rate.

Taienkang's controlled subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. completed enrollment of the first subject in the Phase IIb clinical trial of CKBA cream for the treatment of rosacea.

Taienkang's wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for cisplatin polymer micelles for injection.

Tai Enkang's wholly-owned subsidiary Huabo Kaisheng won the bid for baricitinib tablets (2mg*28 tablets/box) in the 12th national centralized drug procurement.